_id

690f3752ccc777a4e85d17d7

Ticker

BNTX

Name

BioNTech SE

Exchange

NASDAQ

Address

An der Goldgrube 12, Mainz, Germany, 55131

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://www.biontech.de

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Last Close

94.81

Volume

1046218

Current Price

93.81

Change

-1.0547410610695074

Last Updated

2025-11-28T13:03:25.731Z

Image

-

Ipo Date

2019-10-10T00:00:00.000Z

Market Cap

24694773760

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.6061291666666665

Sentiment Sources

48

Rating

4.381

Target Price

136.9055

Strong Buy

13

Buy

3

Hold

5

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

1518900000

Cost Of Revenue

148300000

Gross Profit

1370600000

Operating Expenses

1417500000

Operating Income

-46900000

Interest Expense

399077

Pretax Income

24700000

Net Income

-28700000

Eps

-0.12000000033449477

Dividends Per Share

-

Shares Outstanding

240455450

Income Tax Expense

53400000

EBITDA

149299077

Operating Margin

-3.0877608795839095

Total Other Income Expense Net

71600000

Cash

10092900000

Short Term Investments

4434700000

Receivables

699700000

Inventories

225700000

Total Current Assets

15830700000

Property Plant Equipment

1240700000

Total Assets

21341100000

Payables

399800000

Short Term Debt

53400000

Long Term Debt

192000000

Total Liabilities

2863800000

Equity

18477300000

Depreciation

145133646

Change In Working Capital

730418370

Cash From Operations

854590191

Capital Expenditures

43454091

Cash From Investing

-995852381

Cash From Financing

-14028702

Net Change In Cash

-195695075

PE

-

PB

1.214258843957721

ROE

-0.15532572399647135

ROA

-0.13448229004128184

FCF

811136100

Fcf Percent

0.5340286391467509

Piotroski FScore

2

Health Score

54

Deep Value Investing Score

7

Defensive Investing Score

7

Dividend Investing Score

3

Economic Moat Investing Score

6.8

Garp Investing Score

6

Growth Investing Score

4.5

Momentum Investing Score

4.5

Net Net Investing Score

3

Quality Investing Score

4.5

Value Investing Score

5

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

1518900000

Quarters > 0 > income Statement > cost Of Revenue

148300000

Quarters > 0 > income Statement > gross Profit

1370600000

Quarters > 0 > income Statement > operating Expenses

1417500000

Quarters > 0 > income Statement > operating Income

-46900000

Quarters > 0 > income Statement > interest Expense

399077

Quarters > 0 > income Statement > pretax Income

24700000

Quarters > 0 > income Statement > net Income

-28700000

Quarters > 0 > income Statement > eps

-0.12000000033449477

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

239166666

Quarters > 0 > income Statement > income Tax Expense

53400000

Quarters > 0 > income Statement > EBITDA

149299077

Quarters > 0 > income Statement > operating Margin

-3.0877608795839095

Quarters > 0 > income Statement > total Other Income Expense Net

71600000

Quarters > 0 > balance Sheet > cash

10092900000

Quarters > 0 > balance Sheet > short Term Investments

4434700000

Quarters > 0 > balance Sheet > receivables

699700000

Quarters > 0 > balance Sheet > inventories

225700000

Quarters > 0 > balance Sheet > total Current Assets

15830700000

Quarters > 0 > balance Sheet > property Plant Equipment

1240700000

Quarters > 0 > balance Sheet > total Assets

21341100000

Quarters > 0 > balance Sheet > payables

399800000

Quarters > 0 > balance Sheet > short Term Debt

53400000

Quarters > 0 > balance Sheet > long Term Debt

192000000

Quarters > 0 > balance Sheet > total Liabilities

2863800000

Quarters > 0 > balance Sheet > equity

18477300000

Quarters > 0 > cash Flow > net Income

-33537324

Quarters > 0 > cash Flow > depreciation

145133646

Quarters > 0 > cash Flow > change In Working Capital

730418370

Quarters > 0 > cash Flow > cash From Operations

854590191

Quarters > 0 > cash Flow > capital Expenditures

43454091

Quarters > 0 > cash Flow > cash From Investing

-995852381

Quarters > 0 > cash Flow > cash From Financing

-14028702

Quarters > 0 > cash Flow > net Change In Cash

-195695075

Quarters > 0 > ratios > PE

-0.12000000033449477

Quarters > 0 > ratios > PB

1.214258843957721

Quarters > 0 > ratios > ROE

-0.15532572399647135

Quarters > 0 > ratios > ROA

-0.13448229004128184

Quarters > 0 > ratios > FCF

811136100

Quarters > 0 > ratios > Piotroski FScore

2

Quarters > 0 > ratios > fcf Percent

0.5340286391467509

Quarters > 0 > health Score

54

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

260800000

Quarters > 1 > income Statement > cost Of Revenue

76400000

Quarters > 1 > income Statement > gross Profit

184400000

Quarters > 1 > income Statement > operating Expenses

685500000

Quarters > 1 > income Statement > operating Income

-501100000

Quarters > 1 > income Statement > interest Expense

3292085

Quarters > 1 > income Statement > pretax Income

-402700000

Quarters > 1 > income Statement > net Income

-386600000

Quarters > 1 > income Statement > eps

-1.6

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

241625000

Quarters > 1 > income Statement > income Tax Expense

-16100000

Quarters > 1 > income Statement > EBITDA

-348300000

Quarters > 1 > income Statement > operating Margin

-192.13957055214723

Quarters > 1 > income Statement > total Other Income Expense Net

98400000

Quarters > 1 > balance Sheet > cash

10269500000

Quarters > 1 > balance Sheet > short Term Investments

3767200000

Quarters > 1 > balance Sheet > receivables

1446700000

Quarters > 1 > balance Sheet > inventories

230700000

Quarters > 1 > balance Sheet > total Current Assets

15929100000

Quarters > 1 > balance Sheet > property Plant Equipment

1242100000

Quarters > 1 > balance Sheet > total Assets

21637600000

Quarters > 1 > balance Sheet > payables

504200000

Quarters > 1 > balance Sheet > short Term Debt

52400000

Quarters > 1 > balance Sheet > long Term Debt

217200000

Quarters > 1 > balance Sheet > total Liabilities

3132500000

Quarters > 1 > balance Sheet > equity

18505100000

Quarters > 1 > cash Flow > net Income

-438530491

Quarters > 1 > cash Flow > depreciation

57850633

Quarters > 1 > cash Flow > change In Working Capital

570123146

Quarters > 1 > cash Flow > cash From Operations

132136978

Quarters > 1 > cash Flow > capital Expenditures

567898041

Quarters > 1 > cash Flow > cash From Investing

-26670786

Quarters > 1 > cash Flow > cash From Financing

-14939930

Quarters > 1 > cash Flow > net Change In Cash

1053123595

Quarters > 1 > ratios > PE

-1.6

Quarters > 1 > ratios > PB

1.2248969878574014

Quarters > 1 > ratios > ROE

-2.0891538008440915

Quarters > 1 > ratios > ROA

-1.7867046252819165

Quarters > 1 > ratios > FCF

-435761063

Quarters > 1 > ratios > Piotroski FScore

2

Quarters > 1 > ratios > fcf Percent

-1.6708629716257668

Quarters > 1 > health Score

36

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

182800000

Quarters > 2 > income Statement > cost Of Revenue

83800000

Quarters > 2 > income Statement > gross Profit

99000000

Quarters > 2 > income Statement > operating Expenses

633100000

Quarters > 2 > income Statement > operating Income

-534100000

Quarters > 2 > income Statement > interest Expense

6223037

Quarters > 2 > income Statement > pretax Income

-445400000

Quarters > 2 > income Statement > net Income

-415800000

Quarters > 2 > income Statement > eps

-1.729999998626984

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

240346821

Quarters > 2 > income Statement > income Tax Expense

-29600000

Quarters > 2 > income Statement > EBITDA

-368700000

Quarters > 2 > income Statement > operating Margin

-292.17724288840265

Quarters > 2 > income Statement > total Other Income Expense Net

88700000

Quarters > 2 > balance Sheet > cash

10184900000

Quarters > 2 > balance Sheet > short Term Investments

3924900000

Quarters > 2 > balance Sheet > receivables

1027000000

Quarters > 2 > balance Sheet > inventories

254400000

Quarters > 2 > balance Sheet > total Current Assets

15625500000

Quarters > 2 > balance Sheet > property Plant Equipment

1268000000

Quarters > 2 > balance Sheet > total Assets

21182400000

Quarters > 2 > balance Sheet > payables

443800000

Quarters > 2 > balance Sheet > short Term Debt

55500000

Quarters > 2 > balance Sheet > long Term Debt

237500000

Quarters > 2 > balance Sheet > total Liabilities

2255800000

Quarters > 2 > balance Sheet > equity

18926600000

Quarters > 2 > cash Flow > net Income

-437614191

Quarters > 2 > cash Flow > depreciation

45045424

Quarters > 2 > cash Flow > change In Working Capital

-438350915

Quarters > 2 > cash Flow > cash From Operations

-821658007

Quarters > 2 > cash Flow > capital Expenditures

650527492

Quarters > 2 > cash Flow > cash From Investing

1312211097

Quarters > 2 > cash Flow > cash From Financing

-14523991

Quarters > 2 > cash Flow > net Change In Cash

893281530

Quarters > 2 > ratios > PE

-1.729999998626984

Quarters > 2 > ratios > PB

1.1912829181157736

Quarters > 2 > ratios > ROE

-2.196908055329536

Quarters > 2 > ratios > ROA

-1.9629503738953094

Quarters > 2 > ratios > FCF

-1472185499

Quarters > 2 > ratios > Piotroski FScore

0

Quarters > 2 > ratios > fcf Percent

-8.053531176148796

Quarters > 2 > health Score

34

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

1190000000

Quarters > 3 > income Statement > cost Of Revenue

243500000

Quarters > 3 > income Statement > gross Profit

946500000

Quarters > 3 > income Statement > operating Expenses

797900000

Quarters > 3 > income Statement > operating Income

148600000

Quarters > 3 > income Statement > interest Expense

7400000

Quarters > 3 > income Statement > pretax Income

301200000

Quarters > 3 > income Statement > net Income

259500000

Quarters > 3 > income Statement > eps

1.0799999990011562

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

240277778

Quarters > 3 > income Statement > income Tax Expense

41700000

Quarters > 3 > income Statement > EBITDA

464400000

Quarters > 3 > income Statement > operating Margin

12.487394957983193

Quarters > 3 > income Statement > total Other Income Expense Net

152600000

Quarters > 3 > balance Sheet > cash

9761900000

Quarters > 3 > balance Sheet > short Term Investments

7021700000

Quarters > 3 > balance Sheet > receivables

1523900000

Quarters > 3 > balance Sheet > inventories

283300000

Quarters > 3 > balance Sheet > total Current Assets

18803500000

Quarters > 3 > balance Sheet > property Plant Equipment

1183400000

Quarters > 3 > balance Sheet > total Assets

22529700000

Quarters > 3 > balance Sheet > payables

426700000

Quarters > 3 > balance Sheet > short Term Debt

39500000

Quarters > 3 > balance Sheet > long Term Debt

214700000

Quarters > 3 > balance Sheet > total Liabilities

3118600000

Quarters > 3 > balance Sheet > equity

19411100000

Quarters > 3 > cash Flow > net Income

276806675

Quarters > 3 > cash Flow > depreciation

176430921

Quarters > 3 > cash Flow > change In Working Capital

-745373215

Quarters > 3 > cash Flow > cash From Operations

-501206886

Quarters > 3 > cash Flow > capital Expenditures

100488023

Quarters > 3 > cash Flow > cash From Investing

649243368

Quarters > 3 > cash Flow > cash From Financing

-8090154

Quarters > 3 > cash Flow > net Change In Cash

-633087380

Quarters > 3 > ratios > PE

1.0799999990011562

Quarters > 3 > ratios > PB

1.1612148901494506

Quarters > 3 > ratios > ROE

1.3368639592810299

Quarters > 3 > ratios > ROA

1.1518129402522004

Quarters > 3 > ratios > FCF

-601694909

Quarters > 3 > ratios > Piotroski FScore

2

Quarters > 3 > ratios > fcf Percent

-0.5056259739495799

Quarters > 3 > health Score

51

Valuation > metrics > PE

-0.12000000033449477

Valuation > metrics > PB

1.214258843957721

Valuation > final Score

80

Valuation > verdict

Fair

Profitability > metrics > ROE

-0.15532572399647135

Profitability > metrics > ROA

-0.1812933098346883

Profitability > metrics > Net Margin

-0.01889525314372243

Profitability > final Score

0

Profitability > verdict

Weak

Risk > metrics > Debt Equity

0.15499017713626992

Risk > metrics > Interest Coverage

-117.52118012313413

Risk > final Score

-410

Risk > verdict

High

Liquidity > metrics > Current Ratio

34.93093556928508

Liquidity > metrics > Quick Ratio

34.43292144748455

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

80

Prev Valuations > 1

80

Prev Valuations > 2

100

Prev Profitabilities > 0

0

Prev Profitabilities > 1

0

Prev Profitabilities > 2

37

Prev Risks > 0

-549

Prev Risks > 1

-283

Prev Risks > 2

100

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-16T22:28:09.704Z